Related Experiment Video

Updated: Aug 11, 2026

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures
08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids

G W Bazill1, T M Dexter

  • 1Paterson Institute for Cancer Research, Manchester, U.K.

Biochemical Pharmacology
|January 15, 1989
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Aug 11, 2026

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures
08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Articles linked to this work by shared authors, journal, and citation graph.

Haemopoietic growth factors: their role in cell development and their clinical use.

Cytotechnology·2012

Culturing Primitive Hemopoietic Cells : Long-Term Mouse Marrow Cultures and the Establishment of Factor-Dependent (FDCP-Mix) Hemopoietic Cell Lines.

Methods in molecular biology (Clifton, N.J.)·2011

[Study on expression of adherent proteins related to regulation of hematopoiesis in long-term cultured human bone marrow stromal cells].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2005

A minimal serpin promoter with high activity in haematopoietic progenitors and activated T cells.

The hematology journal : the official journal of the European Haematology Association·2002

Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation.

Oncogene·2000

The role of the Wellcome Trust in support of biomedical research.

Journal of the Royal College of Physicians of London·2000

Mechanisms of cetuximab resistance in head and neck squamous cell Carcinoma: Focus on the EGFR-ERK pathway.

Biochemical pharmacology·2026

Role and mechanism of action of PINK1/Parkin-mediated mitophagy in nonylphenol-induced podocyte apoptosis and glomerulonephritis.

Biochemical pharmacology·2026

Glycosylated steroidal saponins suppress HNSCC progression by targeting the RAS-ERK pathway.

Biochemical pharmacology·2026

The PHLPP paradox revisited: from canonical AKT phosphatases to signaling pseudoenzymes in human disease.

Biochemical pharmacology·2026

Artesunate targets STAT3 to alleviate Hodgkin's lymphoma via JAK-STAT/PD-L1 axis.

Biochemical pharmacology·2026

Biochemistry of protozoan Metacaspases: Structure, processing, and inhibition.

Biochemical pharmacology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us